Citadel Advisors’s Accelerate Diagnostics AXDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-23,451
| Closed | -$16.4K | – | 12512 |
|
|
2025
Q1 | $16.4K | Sell |
23,451
-11,961
| -34% | -$13.6K | ﹤0.01% | 13282 |
|
|
2024
Q4 | $42.5K | Buy |
35,412
+22,900
| +183% | +$38K | ﹤0.01% | 12555 |
|
|
2024
Q3 | $21.4K | Buy |
+12,512
| New | +$18.5K | ﹤0.01% | 12729 |
|
|
2024
Q1 | – | Sell |
-15,446
| Closed | -$60.5K | – | 14534 |
|
|
2023
Q4 | $60.5K | Buy |
+15,446
| New | +$81.7K | ﹤0.01% | 11585 |
|
|
2023
Q1 | – | Sell |
-912
| Closed | -$5.48K | – | 14690 |
|
|
2022
Q4 | $6.44K | Sell |
912
-4,187
| -82% | -$45.7K | ﹤0.01% | 13917 |
|
|
2022
Q3 | $78K | Sell |
5,099
-113,627
| -96% | -$1.88M | ﹤0.01% | 11295 |
|
|
2022
Q2 | $1.18M | Buy |
118,726
+116,930
| +6,511% | +$1.03M | ﹤0.01% | 6649 |
|
|
2022
Q1 | $26K | Sell |
1,796
-6,486
| -78% | -$185K | ﹤0.01% | 13161 |
|
|
2021
Q4 | $432K | Sell |
8,282
-3,040
| -27% | -$169K | ﹤0.01% | 10031 |
|
|
2021
Q3 | $660K | Buy |
11,322
+9,567
| +545% | +$624K | ﹤0.01% | 9208 |
|
|
2021
Q2 | $141K | Sell |
1,755
-1,826
| -51% | -$145K | ﹤0.01% | 12557 |
|
|
2021
Q1 | $298K | Buy |
3,581
+2,187
| +157% | +$222K | ﹤0.01% | 10869 |
|
|
2020
Q4 | $106K | Sell |
1,394
-325
| -19% | -$29.1K | ﹤0.01% | 10186 |
|
|
2020
Q3 | $183K | Buy |
+1,719
| New | +$239K | ﹤0.01% | 8873 |
|
|
2020
Q2 | – | Sell |
-18,474
| Closed | -$1.82M | – | 9750 |
|
|
2020
Q1 | $1.54M | Buy |
18,474
+4,363
| +31% | +$614K | ﹤0.01% | 4572 |
|
|
2019
Q4 | $2.38M | Buy |
14,111
+7,766
| +122% | +$1.28M | ﹤0.01% | 4131 |
|
|
2019
Q3 | $1.18M | Sell |
6,345
-3,918
| -38% | -$757K | ﹤0.01% | 5302 |
|
|
2019
Q2 | $2.35M | Buy |
10,263
+8,814
| +608% | +$1.72M | ﹤0.01% | 4246 |
|
|
2019
Q1 | $304K | Sell |
1,449
-5,373
| -79% | -$1.01M | ﹤0.01% | 7591 |
|
|
2018
Q4 | $785K | Buy |
6,822
+1,425
| +26% | +$211K | ﹤0.01% | 5686 |
|
|
2018
Q3 | $1.24M | Buy |
5,397
+2,925
| +118% | +$647K | ﹤0.01% | 5173 |
|
|
2018
Q2 | $551K | Buy |
+2,472
| New | +$553K | ﹤0.01% | 6207 |
|
|
2017
Q4 | – | Sell |
-2,956
| Closed | -$693K | – | 7944 |
|
|
2017
Q3 | $664K | Buy |
2,956
+110
| +4% | +$27K | ﹤0.01% | 4913 |
|
|
2017
Q2 | $778K | Buy |
+2,846
| New | +$771K | ﹤0.01% | 4476 |
|
|
2016
Q3 | – | Sell |
-2,377
| Closed | -$526K | – | 7223 |
|
|
2016
Q2 | $342K | Buy |
2,377
+77
| +3% | +$10.3K | ﹤0.01% | 5023 |
|
|
2016
Q1 | $331K | Buy |
2,300
+1,783
| +345% | +$252K | ﹤0.01% | 4969 |
|
|
2015
Q4 | $111K | Sell |
517
-606
| -54% | -$111K | ﹤0.01% | 6565 |
|
|
2015
Q3 | $182K | Buy |
1,123
+1,004
| +844% | +$217K | ﹤0.01% | 6268 |
|
|
2015
Q2 | $31K | Buy |
+119
| New | +$28.4K | ﹤0.01% | 7931 |
|
|
2015
Q1 | – | Sell |
-93
| Closed | -$19.4K | – | 8511 |
|
|
2014
Q4 | $18K | Sell |
93
-793
| -90% | -$170K | ﹤0.01% | 7886 |
|
|
2014
Q3 | $190K | Buy |
886
+672
| +314% | +$131K | ﹤0.01% | 5779 |
|
|
2014
Q2 | $56K | Buy |
+214
| New | +$46.7K | ﹤0.01% | 6673 |
|
Other funds holding AXDX
Citadel Advisors's AXDX Position: Q2 2025 in Review
Citadel Advisors sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 23,451 shares — an estimated $16.4K sold.
Citadel Advisors first reported a position in AXDX in Q2 2014 and held it in 32 quarters. The position peaked at $2.38M in Q4 2019. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.
- Citadel Advisors reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 23,451 Accelerate Diagnostics shares in Q2 2025, an estimated $16.4K.
- Citadel Advisors first reported a position in Accelerate Diagnostics in Q2 2014 and held it in 32 quarters.
- Citadel Advisors's Accelerate Diagnostics position peaked at $2.38M in Q4 2019.
- 3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.